AbCellera Biologics Inc. (ABCL)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 4
Bullish: place a GTC buy stop at 6.87 above the 6.86 high; use 6.34 as the protective stop, 7.93 as target 1, and 8.73 as target 2. Liquidity and event checks are clear, and the trade only activates on breakout confirmation.
Company overview
AbCellera Biologics Inc. develops an advanced AI-driven platform for antibody discovery, analyzing natural immune systems to create pharmaceutical drugs. The company has 156 discovery programs and collaborates with 36 partners, including Eli Lilly. Founded in 2012, it is headquartered in Vancouver, Canada.
Fundamental
fairAbCellera's strong liquidity is offset by high R&D costs and negative profitability, resulting in a mixed fundamental outlook.
AbCellera has strong liquidity (about $505M of cash and marketable securities per the latest 10-Q) but continues to run large losses and negative free cash flow. Valuation is demanding (EV/Sales ~26.49x; free-cash-flow yield ~-9.30%), so the equity is largely a bet on pipeline/partner milestones—highlighted by the June 2026 Jazz collaboration with $56M upfront and significant contingent payments. Overall fundamentals are mixed: balance-sheet strength offsets high R&D burn and clinical/regulatory risk (fundamentalScore 3/5).
Sentiment
goodRecent partnership announcements have bolstered media sentiment, while legal and regulatory checks show no significant issues.
An announced June 17 Jazz Pharmaceuticals collaboration is the only clearly actionable near-term catalyst and has been framed positively by coverage; media sentiment in the last ~14d is bullish and stronger than the 30–90d baseline. Legal/regulatory checks showed no regulator-confirmed investigations, and the Red-Flag Screen is clean (no cap).
Technical
goodThe stock is in a strong uptrend, supported by momentum indicators and trading above key moving averages.
Trend and momentum both favor the bulls: price sits above SMA20/50/200 and EMA9/21, MACD is positive and back above its signal, and ADX 45.65 confirms a strong directional move. Because Williams %R is near overbought and the stock is testing the current high, the clean entry is a buy-stop above 6.86 rather than chasing under resistance.
You’re looking at 2026-06-25 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.